STOMP Study: Effective Selinexor Regimen in Multitherapy Combo

Noa Biran, MD, delves into the phase II STOMP study, highlighting selinexor’s efficacy with various backbones like pomalidomide, carfilzomib, daratumumab, and reviews dosing strategies and proactive management of associated toxicities.

EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma

EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape

EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen

EP: 4.Examining Selinexor Role in RRMM Treatment

Now Viewing

EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo

EP: 6.Sequencing Selinexor With Novel BCMA Therapies

EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being

EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Recent Videos

Related Content

---

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy

March 4th 2024

Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.

Related Content

---

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy

March 4th 2024

Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.